Pirfenidone Tablet
Product Images NDC 50228-442

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 50228-442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pirfenidone 02)

This appears to be a table or chart showing the percentage of patients experiencing decline or improvement in lung function (%FVC) after treatment with Pirfenidone or placebo for 52 weeks. The table shows the absolute change in %FVC from baseline.*

FDA Label Image

Figure 2 (Pirfenidone 03)

FDA Label Image

Figure 3 (Pirfenidone 04)

The text describes a clinical trial that compares Pirfenidone versus placebo on the percentage of patients that are still alive. The study included 623 patients who received Pirfenidone and 624 patients who received placebo. The text also shows a graph with the percentage of patients still alive on the y-axis and the time in weeks on the x-axis. Unfortunately, it is not possible to interpret the results of the clinical trial as the only text given is a table with survival rates and a graph.*

FDA Label Image

Principal Display Panel (267 mg 30 Tablets)

This text appears to be a description of a medication called Pirfenidone sold in tablets. It includes the NDC code, the recommended dosage, and instructions to keep the medication out of reach of children. It also provides information about the manufacturer, ScieGien Pharmaceuticals, Inc. *

FDA Label Image

Principal Display Panel (267 mg 1,000 Tablets)

Each tablet of Pirfenidone contains 267mg of the active ingredient. It is recommended to refer to the package insert for complete prescribing information along with the usual dosage. The tablets should be stored at a temperature between 15 to 30°C (59° to 86°F). The medicine should be kept out of children's reach. It is produced by ScieGen Pharmaceuticals, Inc. Lot and expiry details are available on the packaging. The product is available only on prescription.*

FDA Label Image

Principal Display Panel (801 mg 30 Tablets)

This is a description of a medication called Pirfenidone in the form of a film-coated tablet. Each tablet contains 0.1mg of Pirfenidone. The usual dosage and full prescribing information can be found in the package insert. The tablets should be stored between 15° to 30°C (59° t0 36°F). The medication is manufactured by ScieGen Pharmaceuticals, Inc. and is sold in a bottle containing 30 tablets. This medication should be kept out of the reach of children. The text also includes the NDC number and information related to expiration.*

FDA Label Image

Principal Display Panel (801 mg 500 Tablets)

Each package of Pirfenidone Tablets contains 500 tablets with usual dosage and prescribing formation. The tablets should be stored at room temperature not exceeding 25°C and should be kept out of reach of children. The manufacturer is SceGen Pharmaceutical, Inc located in Hauppauge, NY.*

FDA Label Image

Chemical Structure (Pirfenidone Str 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.